[go: up one dir, main page]

GT200600414A - Sal de glucuranato de compuesto de piperazine - Google Patents

Sal de glucuranato de compuesto de piperazine

Info

Publication number
GT200600414A
GT200600414A GT200600414A GT200600414A GT200600414A GT 200600414 A GT200600414 A GT 200600414A GT 200600414 A GT200600414 A GT 200600414A GT 200600414 A GT200600414 A GT 200600414A GT 200600414 A GT200600414 A GT 200600414A
Authority
GT
Guatemala
Prior art keywords
salt
glucuranate
piperazine
composite
piperazine composite
Prior art date
Application number
GT200600414A
Other languages
English (en)
Inventor
Subodh S Deshmukh
Ali Kadum
Christopher R Diorio
Eric C Ehrnsperger
Mahdi B Fawzi
Syed Muzafar Shah
Mahmoud Mirmehrabi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37603202&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200600414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200600414A publication Critical patent/GT200600414A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN PROVEE UNA FORMA DE SAL Y COMPOSICIONES, ÚTILES COMO UN MODULADOR DE UNO O MAS GPCR Y QUE EXHIBEN CARACTERÍSTICAS DESEABLES PARA LOS MISMOS.
GT200600414A 2005-09-12 2006-09-08 Sal de glucuranato de compuesto de piperazine GT200600414A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71616705P 2005-09-12 2005-09-12

Publications (1)

Publication Number Publication Date
GT200600414A true GT200600414A (es) 2007-09-20

Family

ID=37603202

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200600414A GT200600414A (es) 2005-09-12 2006-09-08 Sal de glucuranato de compuesto de piperazine

Country Status (20)

Country Link
US (1) US7595310B2 (es)
EP (1) EP1940830A1 (es)
JP (1) JP2009507921A (es)
KR (1) KR20080045285A (es)
CN (1) CN101287730B (es)
AR (1) AR056506A1 (es)
AU (1) AU2006291058B2 (es)
BR (1) BRPI0615853A2 (es)
CA (1) CA2620755A1 (es)
EA (1) EA014942B1 (es)
GT (1) GT200600414A (es)
IL (1) IL189809A0 (es)
MY (1) MY144782A (es)
NO (1) NO20081809L (es)
PE (1) PE20070433A1 (es)
SA (1) SA06270329B1 (es)
TW (1) TW200800974A (es)
UA (1) UA95922C2 (es)
WO (1) WO2007033191A1 (es)
ZA (1) ZA200802310B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine
MY148643A (en) * 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HUP0700353A2 (en) 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
NZ590852A (en) 2008-07-16 2013-03-28 Richter Gedeon Nyrt Pharmaceutical formulations containing dopamine receptor ligands trans-1{ 4-[2-[4-(2,3-dichlorophenyl)-piperizin-1-yl]-ethyl]-cyclohexyl} -3,3-dimethyl-urea also known as cariprazine
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438119A (en) 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4687772A (en) 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4771053A (en) 1987-03-02 1988-09-13 Bristol-Myers Company Method for alleviation of primary depressive disorders
US5162375A (en) 1988-05-06 1992-11-10 Beecham Group P.L.C. Treatment of neuronal degeneration with 5HT1A agonists
US5824680A (en) 1991-08-31 1998-10-20 Bayer Aktiengesellschaft Ipsapirone for the treatment of alzheimer's disease by improving memory
DE4135551A1 (de) 1991-08-31 1993-03-04 Schering Ag Verwendung von antagonisten oder partiellen agonisten am 5-ht1a-rezeptor zur behandlung und praevention von kognitiven stoerungen
US5716960A (en) * 1995-01-13 1998-02-10 U.S. Bioscience Inc. And Individuals Crystalline trimetrexate salts and the process for making the same
SE9900190D0 (sv) 1999-01-22 1999-01-22 Astra Ab New compounds
DE19730989A1 (de) * 1997-07-18 1999-01-21 Merck Patent Gmbh Piperazin-Derivate
PT1007523E (pt) * 1997-07-25 2004-02-27 Lundbeck & Co As H Derivados indole e 2,3-di-ridroindole, sua preparacao e utilizacao
HN1999000146A (es) 1998-09-21 2000-11-11 Pfizer Prod Inc Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
ES2244469T3 (es) 1999-08-23 2005-12-16 Solvay Pharmaceuticals B.V. Fenilpiperazinas como inhibidores de la recaptacion de serotonina.
MXPA02007095A (es) 2000-01-19 2003-04-14 Akzo Nobel Nv Combinacion de farmacos para el tratamiento de la depresion y desordenes relacionados que comprenden mirtazapina.
AR032712A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Un mesilato de derivados de fenilpiperazina y composiciones farmaceuticas que lo contienen
MXPA06001636A (es) 2003-08-13 2006-04-28 Amgen Inc Antagonista del receptor de la hormona concentradora de melanina.
CN1934108A (zh) 2003-12-18 2007-03-21 特瓦制药工业有限公司 齐拉西酮碱的多晶型b2
GT200600416A (es) 2005-09-12 2007-09-20 Sales salicilato y gentisato de un compuesto de piperazina
PE20070523A1 (es) 2005-09-12 2007-06-28 Wyeth Corp Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona
GT200600414A (es) 2005-09-12 2007-09-20 Sal de glucuranato de compuesto de piperazine

Also Published As

Publication number Publication date
BRPI0615853A2 (pt) 2011-05-31
WO2007033191A1 (en) 2007-03-22
EA200800810A1 (ru) 2008-10-30
JP2009507921A (ja) 2009-02-26
IL189809A0 (en) 2008-08-07
SA06270329B1 (ar) 2010-06-15
US20070254876A1 (en) 2007-11-01
EP1940830A1 (en) 2008-07-09
AU2006291058B2 (en) 2011-09-08
CN101287730A (zh) 2008-10-15
CA2620755A1 (en) 2007-03-22
ZA200802310B (en) 2008-12-31
AU2006291058A1 (en) 2007-03-22
AR056506A1 (es) 2007-10-10
US7595310B2 (en) 2009-09-29
CN101287730B (zh) 2012-03-07
UA95922C2 (en) 2011-09-26
KR20080045285A (ko) 2008-05-22
PE20070433A1 (es) 2007-04-24
EA014942B1 (ru) 2011-04-29
NO20081809L (no) 2008-04-14
MY144782A (en) 2011-11-15
TW200800974A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
SV2009003392A (es) Aril pirrolidinas insecticidas
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
ECSP11010822A (es) 4-fenil-1h-pirazoles insecticidas
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
GT201400181A (es) Composicion para el control de plagas que incluye un derivado de iminopiridina novedoso
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CR9786A (es) Compuestos de bencimidazol-tiofeno
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
UY3723Q (es) Aerosol
BRPI0816326A2 (pt) Compostos que modulam cálcio intracelular
CO6311002A2 (es) Agentes fijadores y epitopos wise
CR11361A (es) Moleculas y metodos para modular el componente de complemento
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
CR11488A (es) 4-fenilpiran 3,5-dionas, 4-feniltiopiran-3,5-dionas y 2-fenilciclohexan-1,3,5-trionas como herbicidas
CR20120183A (es) PIPERIDINAS SUSTITUIDAS QUE AUMENTAN LA ACTIVIDAD DE p53 Y SUS USOS
UY31688A1 (es) Plaguicidas
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
GT200600414A (es) Sal de glucuranato de compuesto de piperazine
EA201000258A1 (ru) Новые гербициды
HN2006037713A (es) Compuestos utiles en terapia
DK2373652T3 (da) Substituerede piperidin-spiro-pyrrolidinon- og piperidinon-forbindelser anvendt som h3-modulatorer
ECSP088607A (es) Compuestos y métodos para inhibir la interacción de las proteínas bcl con las parejas de unión